NASDAQ · Biotechnology

Adial Pharmaceuticals, Inc (ADIL) Stock

$3.90 -1.76% NASDAQ: ADIL Healthcare

Valuation

MetricValue
Price$3.90
Market Cap$10.24M
P/E Ratio-0.26
P/B Ratio128.88
P/S Ratio0.00
EPS (TTM)$-2.60
52-Week High$30.25
52-Week Low$1.31
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-265.94%
ROA-198.70%
ROCE-240.64%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio6.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-19.0M$-11.0M$-7.0M$-8.0M$-8.0M
Net Profit$-19.0M$-13.0M$-7.0M$-13.0M$-8.0M
EPS$-653.00$-299.50$-136.00$-17.75$-11.93
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$8.0M$6.0M$5.0M$5.0M$7.0M
Total Liabilities$4.0M$2.0M$1.0M$1.0M$2.0M
Cash$6.0M$4.0M$3.0M$4.0M$6.0M
Borrowings$0$0$0$0$0

Latest News

Adial Pharmaceuticals Closes First $32 Million Tranche of Financing MT Newswires · Jun 16, 2026 Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing GlobeNewswire · Jun 16, 2026 Sector Update: Healthcare Stocks Higher Late Afternoon MT Newswires · Jun 11, 2026 Sector Update: Healthcare MT Newswires · Jun 11, 2026 Top Midday Gainers MT Newswires · Jun 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-11.0M$-7.0M$-7.0M$-6.0M
Investing Cash Flow$0$0$8.0M$0$0
Financing Cash Flow$2.0M$0$0$4.0M$0
Net Cash Flow$2.0M$-2.0M$-1.0M$1.0M$2.0M
Free Cash Flow$-12.0M$-11.0M$0$-7.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA0.30
FCF Yield-97.46%
Quick Ratio5.63
Interest Coverage0.00
Return 1Y-70.59%
Return 3Y-98.45%
Return 5Y-99.83%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXPAcurx Pharmaceuticals, Inc. $1.27 +1.60% -0.36 $5.46M 0.00%
APREAprea Therapeutics, Inc. $0.60 +8.28% -0.64 $7.48M 0.00%
BCDABioCardia, Inc. $1.04 -1.89% -1.54 $15.48M 0.00%
BCLIBrainstorm Cell Therapeutics Inc. $0.98 +6.52% -1.04 $10.81M 0.00%
CDIOCardio Diagnostics Holdings Inc. $1.87 +0.54% -0.71 $5.53M 0.00%

About Adial Pharmaceuticals, Inc

Adial Pharmaceuticals, Inc is led by CEO Cary John Claiborne, employs 5 people, headquartered in US, publicly traded since 2018.

Adial Pharmaceuticals, Inc (ADIL) stock trades at $3.90 with a market capitalization of $10.24M. The stock is valued at a price-to-earnings (P/E) ratio of -0.26, price-to-book of 128.88, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.31 and $30.25, and currently trades 87.1% below its 52-week high.

On profitability, Adial Pharmaceuticals, Inc generates a return on equity (ROE) of -265.94%, return on capital employed of -240.64%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides